Antihypertensive Management in Hypertrophic Obstructive Cardiomyopathy (HOCM) with Elevated Blood Pressure

First‑Line Therapy – Beta‑Blockers

• Beta‑blockers are recommended as the first‑line antihypertensive for all adult HOCM patients (symptomatic or hypertensive). Class I, Level B‑NR. 1
• Use non‑vasodilating agents (e.g., metoprolol, atenolol, bisoprolol) and titrate to achieve a resting heart rate of 50–65 bpm. Class I, Level B‑NR. 1
• Do not label beta‑blocker therapy as “failed” until a physiologic heart rate of 50–60 bpm is reached at the maximally tolerated dose. Class I, Level B‑NR. 1

Second‑Line Therapy – Non‑Dihydropyridine Calcium‑Channel Blockers

• If beta‑blockers are ineffective, not tolerated, or contraindicated, substitute with verapamil or diltiazem. Class I, Level B‑NR. 1
• Verapamil should be initiated at low doses and titrated slowly to a maximum of 480 mg/day. Class I, Level B‑NR. 1
• Contraindications to verapamil (Class III, Harm):
• Caution is advised when using verapamil in patients with:
• Verapamil’s vasodilatory effect can precipitate life‑threatening hypotension and may worsen LVOT obstruction in high‑gradient patients. Class III, Harm. 1
• Diltiazem is an acceptable alternative non‑dihydropyridine calcium‑channel blocker when verapamil is not tolerated. Class I, Level C‑LD. 8

Third‑Line Therapy – Disopyramide (Add‑on)

• Add disopyramide for persistent symptoms despite optimal beta‑blocker or verapamil therapy. Class I, Level B‑R. 1
• Disopyramide must always be combined with a beta‑blocker or verapamil; monotherapy is contraindicated (Class III, Harm) because it can increase ventricular rate during atrial fibrillation. 1

Medications to Avoid (Class III, Harm)

• ACE inhibitors and ARBs – vasodilation may worsen LVOT gradients. 1
• Dihydropyridine calcium‑channel blockers (e.g., nifedipine, amlodipine) – pure vasodilators without negative inotropy increase obstruction. 1
• High‑dose diuretics – volume depletion can exacerbate obstruction. 3
• Digoxin (unless atrial fibrillation is present) – potential for harm in obstructive HCM. 1

Adjunctive Diuretic Therapy

• Low‑dose oral diuretics may be added cautiously (Class IIb, Level C‑EO) when dyspnea persists despite optimal beta‑blocker or calcium‑channel blocker therapy and there is objective evidence of volume overload. 1
• Use extreme caution because volume depletion can worsen LVOT obstruction; diuretics are safer in non‑obstructive HCM. 1

Management of Comorbid Hypertension

• Treat hypertension aggressively according to standard hypertension guidelines (Class I, Level C); uncontrolled hypertension independently worsens outcomes in HOCM. 5

Monitoring Strategy

• Measure resting LVOT gradient before initiating verapamil to ensure safety. 7
• At each visit, monitor blood pressure, heart rate, and symptom burden. (clinical practice)
• Assess for signs of volume overload or heart failure before adding diuretics. 3
• Perform serial echocardiography to track changes in LVOT gradient and ventricular function. (clinical practice)

Common Pitfalls to Avoid

• Do not use vasodilators (ACE‑I, ARBs, dihydropyridine CCBs) as first‑line antihypertensives in HOCM—they worsen obstruction. 1
• Avoid combining beta‑blockers with verapamil, as this increases heart‑failure risk. 7
• Do not employ aggressive diuresis; volume depletion aggravates LVOT obstruction. 3
• Do not declare beta‑blocker failure before achieving a resting HR of 50–60 bpm. 1
• Do not start verapamil in patients with high resting gradients (>80–100 mmHg), hypotension, or severe dyspnea at rest (Class III, Harm). 1